BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 16846527)

  • 41. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
    Kontorovich T; Cohen Y; Nir U; Friedman E
    Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
    Tilanus-Linthorst MM; Alves C; Seynaeve C; Menke-Pluymers MB; Eggermont AM; Brekelmans CT
    Br J Surg; 2006 Aug; 93(8):961-8. PubMed ID: 16758466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
    de Bock GH; Tollenaar RA; Papelard H; Cornelisse CJ; Devilee P; van de Vijver MJ
    Br J Cancer; 2001 Nov; 85(9):1347-50. PubMed ID: 11720473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
    Jing F; Jun L; Yong Z; Wang Y; Fei X; Zhang J; Hu L
    Oncology; 2008; 75(1-2):60-6. PubMed ID: 18784433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
    Bhavani V; Srinivasulu M; Ahuja YR; Hasan Q
    Cancer Biomark; 2009; 5(4):207-13. PubMed ID: 19729830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
    Rice JC; Massey-Brown KS; Futscher BW
    Oncogene; 1998 Oct; 17(14):1807-12. PubMed ID: 9778046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
    King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
    Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.
    Agirre X; Novo FJ; Calasanz MJ; Larráyoz MJ; Lahortiga I; Valgañón M; García-Delgado M; Vizmanos JL
    Mol Carcinog; 2003 Dec; 38(4):201-8. PubMed ID: 14639659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant inactivation of p53 and Chk2 in breast cancer.
    Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
    Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
    Wessels LF; van Welsem T; Hart AA; van't Veer LJ; Reinders MJ; Nederlof PM
    Cancer Res; 2002 Dec; 62(23):7110-7. PubMed ID: 12460933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TP53 mutations in familial breast cancer: functional aspects.
    Gasco M; Yulug IG; Crook T
    Hum Mutat; 2003 Mar; 21(3):301-6. PubMed ID: 12619116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.